NASDAQ:IVVD Invivyd Q4 2024 Earnings Results & Report $0.65 -0.03 (-4.05%) Closing price 10/13/2026 04:00 PM EasternExtended Trading$0.65 +0.01 (+1.08%) As of 07:55 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Invivyd beat analyst expectations on both earnings and revenue in its Q4 2024 results, released March 20, 2025. The company reported EPS of -$0.15 versus the -$0.25 consensus estimate, while revenue of $13.80 million topped the $13.57 million estimate by $0.23 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 20, 2025TimeBefore Market OpensConference Call8:00 AM ET Invivyd EPS ResultsActual EPS-$0.15Consensus EPS -$0.25Beat/MissBeat by +$0.10One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersInvivyd Revenue ResultsActual Revenue$13.80 millionExpected Revenue$13.57 millionBeat/MissBeat by +$233.00 thousandYoY Revenue GrowthN/AUpcoming EarningsInvivyd's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Invivyd Q4 2024 Earnings FAQ Did Invivyd beat earnings estimates for Q4 2024? Invivyd (NASDAQ:IVVD) reported earnings of -$0.15 per share for Q4 2024, beating the consensus estimate of -$0.25. The report was announced on Thursday, March 20, 2025. What was Invivyd's revenue for Q4 2024? Invivyd reported revenue of $13.80 million for Q4 2024, against a consensus estimate of $13.57 million. When is Invivyd's next earnings date? Invivyd's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Invivyd on the company's earnings history page. Invivyd Earnings HeadlinesInvivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome57 minutes ago | globenewswire.comIVVD Share News TodayOctober 12 at 5:47 PM | uk.investing.comThis little-known gold fund distributes cash every FridayGold pays no dividends, no interest, no yield - it just sits there. Yet investors are reportedly collecting up to $1,127 a month from a little-known 15 dollar fund built around it. This fund turns gold's price swings into cash, paid out every single Friday.October 14 at 1:00 AM | Investors Alley (Ad)Arcus Biosciences (NYSE:RCUS) versus Invivyd (NASDAQ:IVVD) Head to Head ReviewOctober 12 at 8:14 AM | americanbankingnews.comBTIG Sticks to Its Buy Rating for Invivyd (IVVD)October 5, 2026 | theglobeandmail.comInvivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 5, 2026 | globenewswire.comSee More Invivyd Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Invivyd? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Invivyd and other key companies, straight to your email. Email Address About InvivydInvivyd (NASDAQ:IVVD) is a clinical-stage biopharmaceutical company focused on developing antibody-based medicines designed to prevent and treat viral diseases. The company’s approach is intended to provide durable protection against rapidly evolving viruses by using engineered monoclonal antibodies that can be updated as pathogens change. Invivyd’s leading product is pemivibart, marketed in the United States under the brand name PEMGARDA. The product received emergency use authorization from the U.S. Food and Drug Administration for pre-exposure prophylaxis against COVID-19 in certain moderately to severely immunocompromised individuals for whom vaccination is not expected to provide adequate protection. Invivyd is also advancing additional antibody candidates for infectious disease indications. The company was founded as Adagio Therapeutics and changed its name to Invivyd in 2023. Based in Waltham, Massachusetts, Invivyd conducts research and clinical development activities intended to support the availability of its antibody therapies in the United States and other markets. The company is led by Mark J. Esser, Ph.D., who serves as president and chief executive officer.View Invivyd ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Tax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
